Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
2.040
-0.020 (-0.97%)
At close: Feb 21, 2025, 4:00 PM
2.146
+0.106 (5.20%)
After-hours: Feb 21, 2025, 7:12 PM EST
Milestone Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Milestone Pharmaceuticals stock have an average target of 13, with a low estimate of 5.00 and a high estimate of 25. The average target predicts an increase of 537.25% from the current stock price of 2.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Milestone Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,125.49% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,125.49% | Oct 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,125.49% | Aug 22, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +341.18% | Aug 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,125.49% | Jul 1, 2024 |
Financial Forecast
Revenue This Year
n/a
from 1.00M
Revenue Next Year
4.69M
EPS This Year
-0.63
from -1.39
EPS Next Year
-1.02
from -0.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 8.0M | 63.0M | |||
| Avg | n/a | 4.7M | 56.6M | |||
| Low | n/a | 1.8M | 49.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 1,242.7% | |||
| Avg | - | - | 1,105.4% | |||
| Low | - | - | 963.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.61 | -0.54 | 0.15 | |||
| Avg | -0.63 | -1.02 | -0.36 | |||
| Low | -0.64 | -1.37 | -0.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.